Nautilus Biotechnology will announce Q2 2025 financial results on July 31, followed by a conference call.
Quiver AI Summary
Nautilus Biotechnology, Inc. has announced that it will release its financial results for the second quarter of 2025 on July 31, 2025, before the market opens. Following the announcement, the company's management will host a conference call at 5:30 a.m. Pacific Time to discuss the results, recent business developments, and future outlook. The call will be accessible via a live webcast on the company's website. Nautilus, based in Seattle with research and development operations in San Carlos, California, is focused on developing technology for protein analysis to advance the field of proteomics and improve human health and medicine.
Potential Positives
- Nautilus Biotechnology is set to report its financial results for the second quarter of 2025, indicating transparency and regular communication with investors.
- The scheduled conference call demonstrates the company's commitment to engaging with stakeholders and discussing its business developments and outlook.
- By highlighting its innovative single-molecule protein analysis platform, Nautilus reinforces its position as a pioneer in the rapidly evolving field of proteomics.
Potential Negatives
- Announcement of financial results suggests the company has not yet achieved profitability, indicating potential ongoing financial difficulties.
- The inclusion of a conference call to discuss business developments may imply the need for transparency about challenges faced, potentially raising concerns among investors.
- The company is described as being in a development stage, which could signal risks associated with product development and market acceptance.
FAQ
When will Nautilus Biotechnology announce its second quarter 2025 financial results?
Nautilus will report its second quarter 2025 financial results on July 31, 2025, before market open.
What time is the Nautilus conference call on July 31, 2025?
The conference call will begin at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
How can I access the Nautilus webcast?
The live audio of the webcast will be available in the "Investors" section of the Nautilus website at www.nautilus.bio.
What is Nautilus Biotechnology's mission?
Nautilus aims to transform proteomics by democratizing access to the proteome and advancing human health and medicine.
Where is Nautilus Biotechnology headquartered?
Nautilus has its corporate headquarters in Seattle, Washington, and its research and development headquarters in San Carlos, California.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NAUT Insider Trading Activity
$NAUT insiders have traded $NAUT stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NAUT stock by insiders over the last 6 months:
- SUJAL M PATEL (CEO, President, and Secretary) has made 2 purchases buying 77,233 shares for an estimated $76,918 and 0 sales.
- ANNA MOWRY (CFO and Treasurer) purchased 15,000 shares for an estimated $11,488
- PARAG MALLICK (Chief Scientist) has made 2 purchases buying 13,500 shares for an estimated $9,885 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NAUT Hedge Fund Activity
We have seen 32 institutional investors add shares of $NAUT stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 686,579 shares (-39.0%) from their portfolio in Q1 2025, for an estimated $591,144
- BLACKROCK, INC. removed 270,074 shares (-8.8%) from their portfolio in Q1 2025, for an estimated $232,533
- CLARIUS GROUP, LLC added 230,054 shares (+36.1%) to their portfolio in Q1 2025, for an estimated $198,076
- JACOBS LEVY EQUITY MANAGEMENT, INC added 225,098 shares (+inf%) to their portfolio in Q1 2025, for an estimated $193,809
- MORGAN STANLEY removed 221,445 shares (-56.3%) from their portfolio in Q1 2025, for an estimated $190,664
- WEXFORD CAPITAL LP removed 220,659 shares (-67.8%) from their portfolio in Q1 2025, for an estimated $189,987
- CITADEL ADVISORS LLC removed 117,292 shares (-53.3%) from their portfolio in Q1 2025, for an estimated $100,988
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio .
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit
www.nautilus.bio
.
Media Contact
[email protected]
Investor Contact
[email protected]
